

# Péricardite aiguë secondaire à une infection à *Mycoplasma Pneumoniae*

## Acute pericarditis associated with *Mycoplasma Pneumoniae* infection

Labbaoui. R <sup>(1,2)</sup>, Amani. S <sup>(1,2)</sup>, Oueslati. N <sup>(1,2)</sup>, Mgimagh. S <sup>(1,2)</sup>, Balhoudi. H <sup>(1)</sup>, Mejaouel. H <sup>(1,2)</sup>

<sup>(1)</sup> Hôpital Ibn Al Jazzar Kairouan, service de pédiatrie

<sup>(2)</sup> Faculté de médecine de Sousse

### ABSTRACT

*Mycoplasma pneumoniae* is the only mycoplasma clearly involved in respiratory tract infections in man. It infects the upper and lower respiratory tracts, leading to a wide range of respiratory and non-respiratory symptoms. We report a 7-year-old-boy case with pericardial effusion secondary to a *M.pneumoniae* infection. He was admitted for dyspnea with chest pain. No other abnormalities were detected on examination. The chest X-ray revealed an enlargement of the heart shape and the echocardiography showed a pericardial effusion. He received cefotaxime and vancomycin without improvement. On the fifth day he presented a maculo-papular skin rash with an important lethargy. The *M. pneumoniae* serology was positive. The patient received intravenous erythromycin and immunoglobulins. He improved within 48 hours.

### RÉSUMÉ

Le *Mycoplasma pneumoniae* est le seul mycoplasme incriminé dans les infections des voies respiratoires chez l'homme. Il infecte les voies respiratoires supérieures et inférieures conduisant à des manifestations respiratoires et non respiratoires. Nous rapportons le cas d'un garçon de 7ans hospitalisé pour épanchement péricardique secondaire à une infection à *M.pneumoniae*. Il a été admis pour dyspnée avec douleur thoracique. La radiographie du thorax a montré une cardiomégalie et l'échocardiographie a révélé un épanchement péricardique. Il a reçu la céfotaxime et la vancomycine sans aucune amélioration. Au cinquième jour, il a présenté une éruption cutanée maculo papuleuse avec une léthargie importante. La sérologie de *M.pneumoniae* était positive. Le patient était mis sous érythromycine par voie intraveineuse et une cure d'immunoglobulines avec une nette amélioration des symptômes.

**Mots clés :** Mycoplasme pneumoniae, péricardite, enfant, macrolide, immunoglobulines.

**Key words :** *Mycoplasma pneumoniae*, pericarditis, child, macrolide, immunoglobulins.

### INTRODUCTION

Insidious pericardial effusion may result from a wide variety of causes. The most common identifiable causes of acute pericarditis in children are bacterial infections, viral pericarditis, inflammatory or connective tissue diseases, malignancies, metabolic diseases, and postpericardiotomy syndrome. Most studies of acute pericarditis in children have been limited to case series of purulent pericarditis or pericarditis with large effusions. The proportion of cases caused by different etiologies including infectious and inflammatory is unclear.[1]

We report here a rare case of a pericardial effusion in a pediatric patient secondary to infection with

*Mycoplasma pneumoniae* (*M.pneumoniae*) where the diagnosis was a challenge.

### CASE REPORT

A previously healthy 7-year-old boy was admitted for fever and chest pain. No medical history was reported. The patient received amoxicillin and ibuprofen for a sore throat for the last week. The patient presented a prolonged fever for one week. The chest pain appeared within the last 24 hours before his admission. On examination, he had a fever (38.9°C) with shortness of breath. He had a tachypnea at 35 breaths/min, a low pulse oximeter to 92%, his blood pressure was 110/70 mmHg and heart rate was 130 beats/min with a reduced heart sounds.

Auteur correspondant :

**Dr Labbaoui Rania**

**Mail :** ranielabbaoui@yahoo.fr

No signs of septic or cardiogenic shock were detected. No other abnormalities were noted. Complete blood count showed an anemia with 9.6 g/dl of hemoglobin, white blood cells at 18000/mm<sup>3</sup> with neutrophils (80%), a normal platelet count and the CRP level was 150mg/l (<8mg/l), troponin 95 ng/l (<15 ng/l), CK 1700 UI/l (0 et 190 UI/l) and procalcitonin to 2.5 ng/ml (< 0.5 ng/ml). The chest X-ray showed a cardiomegaly (figure 1).



**Figure 1 :** Chest X-Ray : cardiomegaly and a basal pneumonia on left side.

A transthoracic echocardiography showed a diffuse pericardial effusion with no signs of tamponade (figure 2). No signs of myocarditis were detected with an estimated ejection fraction of the left ventricular to 65%.



**Figure 2 :** echocardiography showing pericardial effusion.

The diagnosis of pericarditis was made. Infectious cause was mostly suspected due to the septic presentation and the inflammatory syndrome. The patient was admitted to the intensive care unit and received oxygen, Cefotaxime 200 mg/kg/day and Vancomycin 60mg/kg/day. Paracetamol was given for pain and fever. For days later, no improvement noted with persistent fever. No change in the blood test results and in the echocardiography abnormalities. On the fifth day, the patient presented a maculopapular rash with lethargy (figure n°3).



**Figure 3 :** A generalized skin rash of the trunk made of figurative erythematous-violin maculopapular plaques ranging from 1cm to 4 cm in diameter taking a cocardi form appearance in places and targeted by others.

We tested the patient for mycoplasma, Chlamydia, Herpes, EBV, CMV, Parvovirus B19 and hepatitis B and C. An inflammatory cause was excluded with a negative ANA and ANCA antibodies were negatives. M. Pneumoniae serology was positive with IgM and IgG. An acute M. Pneumoniae pericarditis was diagnosed. The patient received IV erythromycin 50mg/kg/day and Immunoglobulin 2g/kg over 48 hours. The patient's symptoms improved on the second day, the oxygen was discontinued, no lethargy and disappearance of the skin rash. An echocardiography showed no cardio-effusion within the seventh day of treatment. So, the diagnosis of a pericardial effusion due to M. pneumoniae was admitted.

## DISCUSSION

M. pneumoniae is the only mycoplasma clearly involved in respiratory tract infections in man. It is the second most frequent agent responsible for community-wide bacterial pneumonia [2].

M. pneumoniae infection is common in children and adolescents, and is often accompanied by extra-pulmonary complications [3]. It is one of the main causes of respiratory tract infections in childhood [4], [5]. The extra-pulmonary complications involving all the main organ systems can occur in association with M. pneumoniae infection as a result of direct invasion of the myocardium by the organism via either the lymphatic or circulatory systems or from the lower respiratory tract by contamination and/or autoimmune response [6], [2]. These symptoms may be isolated, or they may occur before, after or within the respiratory symptoms (table 1).

**Tableau 1 :** Clinical manifestations caused by or associated with Mycoplasma pneumoniae infection [4].

Clinical manifestations	Symptoms
Pulmonary	<ul style="list-style-type: none"> <li>• Tonsillitis, Rhinitis, Pharyngitis</li> <li>• Tracheobronchitis, Bronchiolitis, Bronchopneumonia</li> <li>• Croup</li> <li>• Bronchopneumonia</li> <li>• Atypical pneumonia</li> <li>• Asthma</li> </ul>
Neurological	<ul style="list-style-type: none"> <li>• Encephalitis, Meningoencephalitis, Aseptic meningitis</li> <li>• Cerebral ataxia</li> <li>• Transverse myelitis</li> <li>• Guillain-Barre' syndrome, Polyradiculitis, Peripheral neuropathy</li> <li>• Optic neuritis, Cranial nerve palsies</li> <li>• Stroke</li> <li>• SIADH</li> </ul>
Renal	<ul style="list-style-type: none"> <li>• Glomerulonephritis</li> <li>• Renal failure</li> <li>• Tubulo-interstitial nephritis</li> <li>• IgA neuropathy</li> </ul>

Skin	<ul style="list-style-type: none"> <li>• Erythematous maculo-papular and vesicular rashes</li> <li>• Generalised ulcerative stomatitis, Bullous exanthems</li> <li>• Stevens–Johnson syndrome</li> <li>• Erythematous maculo-papular rash, Vesicular rash</li> <li>• Erythema nodosum, Pityriasis rosea</li> <li>• Toxic epidermal necrolysis, Bullous erythema multiforme</li> <li>• Subcorneal pustular dermatosis</li> </ul>
ophthalmological	<ul style="list-style-type: none"> <li>• Conjunctivitis, Anterior uveitis</li> <li>• Retinitis, Retinal haemorrhages</li> <li>• Iritis, Optic disk swelling</li> </ul>
Musculoskeletal	<ul style="list-style-type: none"> <li>• Arthralgias, Septic arthritis</li> <li>• Myalgias, Acute rhabdomyolysis</li> </ul>
Haematological	<ul style="list-style-type: none"> <li>• Haemolytic anaemia</li> <li>• Intravascular coagulation</li> <li>• Aplastic anaemia</li> <li>• Thrombotic thrombocytopenic purpura</li> <li>• Urticarial vasculitis</li> <li>• Leukocytoclastic vasculitis</li> <li>• Henoch-Schoenlein purpura</li> </ul>
Cardiovascular	<ul style="list-style-type: none"> <li>• Pericarditis, Myocarditis</li> <li>• Pericardial effusion</li> <li>• Raynaud phenomenon</li> </ul>
Gastrointestinal	<ul style="list-style-type: none"> <li>• Diarrhoea, Cholestatic hepatitis, Pancreatitis</li> <li>• Hypoechoic lesions in spleen</li> </ul>

Only 7-1% of the infected patients develop pneumonia, while 5-20% may develop pleural effusion[7]. However, Paz and Potasman[8] found that 43% of patients with carditis had pneumonia and 19% had pleural effusions. These rather high values raise the question of whether the more severe respiratory cases are indeed associated with the development of carditis. Extra-pulmonary complications of *M.pneumoniae*, such as central nervous system (CNS) manifestations and arthritis, appear to occur more frequently in children. However, the mean age of the patients with *M.pneumoniae*-associated carditis appears to be relatively greater[9]. The incidence of cardiac involvement ranged from 1% to 8.5% in persons with serological evidence of infection[10]. The cardiac complications of *M.pneumoniae* infections include pericarditis and myocarditis possibly leading to cardiac tamponade or arrhythmias[11]. The initial diagnostic testing for pericarditis typically includes chest Xray; however, it is common for the cardiac silhouette and pulmonary vascular markings to be normal. The ECG changes are not always specific for pericarditis. The most common abnormality seen is diffuse ST-segment elevation in the precordial leads of the ECG without T-wave inversion in the acute phase and PR-interval depression. A transthoracic echocardiogram is performed to help distinguish pericarditis from myocarditis, in which there is usually cardiac dysfunction as opposed to pericarditis in which the function is normal. The echocardiogram establishes the presence and size of a pericardial effusion. The best method for identifying pathogenic agents associated with pericarditis is to obtain tissue directly from the involved area or a pericardial

effusion for use in microbiologic cultures[8], [12]. However, there are significant risks associated with obtaining a sample of tissue from the pericardium. *M.pneumoniae* infections cannot be diagnosed by clinical findings alone, especially when they present with extra-pulmonary symptoms. Before the availability of new technologies, cold agglutinins were used to confirm a diagnosis of *M. Pneumoniae* infection. Cold agglutinins are IgM antibodies directed to antigen 1 on erythrocytes. They are produced 1 or 2 weeks after infection in 50% of patients and may persist for several weeks. Lack of sensitivity and specificity render cold agglutinins irrelevant for diagnosis as they may also be present in infections caused by viruses and other bacteria [13]. While culture is the reference standard for diagnosis, it is expensive and time-consuming and requires specialized media and technical expertise. Diagnosis of *M. pneumoniae* infection is usually performed by serological methods, such as passive agglutination, complement fixation and ELISA. A combination of PCR and serology is recommended for reliable diagnosis [14]. Serological tests for anti-*Mycoplasma* antibody represent the most common method for retrospective diagnosis of *Mycoplasma* infections. Evidence of seroconversion by collection of acute and convalescent sera is the optimal method for retrospective *Mycoplasma* diagnosis. The sensitivity and specificity of passive agglutination with single serum samples varies with the titre cut-off value used. It is suggested that a titer of 1:80 or 1:160 is useful for the diagnosis of *M. pneumoniae* infection in children. Passive agglutination serology using paired sera shows good agreement with PCR results [14]. ELISA is more sensitive than culture for detecting acute infection, has sensitivity comparable to PCR, but may be less sensitive than passive agglutination[14]. Complement fixation tests, indirect immunofluorescent assays and particle-agglutination assays have low sensitivity and specificity. PCR has been recommended for more sensitive detection of *M. pneumoniae*, especially for patients with neurological and other extra-pulmonary manifestations[15]. While there is no disagreement concerning the optimum antibiotic management of *M. pneumoniae* respiratory tract infections, controversy and limited clinical evidence characterizes the current situation concerning management of extra-pulmonary conditions associated with *M. pneumoniae*. Macrolides, tetracyclines and fluoroquinolones eliminate *Mycoplasma* efficiently both in vivo and in vitro. Macrolides are the antibiotics of choice for treating *M. pneumoniae* infections in both adults and children. New macrolides are better tolerated, require fewer doses and have a shorter treatment duration than older compounds. A potential problem in the antimicrobial management of *M. pneumoniae* infections is the emergence of macrolide resistance, reported initially in Japan during 2000 [16]. Treatment of children with fluoroquinolones may be possible; however, these agents are not yet approved for use in children by the Federal Drug Administration [4]. While *M. pneumoniae* infections in the upper respiratory tract may improve following antibiotic treatment, this is not generally recommended, as such

infections are usually self-limiting. Some clinicians recommend treatment of acute tonsillopharyngitis to prevent the risk of recurrence of respiratory illness [11]. Controversies in the management of non-respiratory conditions associated with *M. pneumoniae* infections result from the limited knowledge of their pathogenesis. While some extra-pulmonary conditions may be caused by a post-inflammatory response to *M. pneumoniae* infection, other conditions may result from direct tissue damage caused by this organism. Steroids have been used in selected patients with severe CNS syndromes, based on the presumed role of cytokines in inflammation, despite the absence of any objective prospective evaluation in clinical trials [15] [17]. Case reports suggest that high-dose steroid therapy may reverse neurological manifestations in children. Aggressive therapy with steroids and high-dosage immunoglobulins in children was reported to improve outcome in cases of stroke related to *M. pneumoniae* infection [18]. Even severe cases of *M. pneumoniae* in children also benefit from the use of steroids in conjunction with antibiotics [19]. In addition to steroids, other therapies, including plasmapheresis, plasma exchange and intravenous IgG, have been used to treat patients with severe CNS complications. None of these strategies has been tested in randomized double-blind clinical trials, and their benefit therefore remains unclear. Plasmapheresis was reported to be effective in cases of transverse myelitis or polyradiculitis [4]. Despite the absence of evidence, it seems reasonable to consider the use of immunomodulatory therapies, together with antibiotics, in severe cases. The use of antibiotics for treating CNS conditions associated with *M. pneumoniae* infection is also reported to have variable results.

## CONCLUSION

*Mycoplasma pneumoniae* pericarditis is a rare entity, and, to our knowledge, it has rarely been previously described within children in the literature. In addition, this case highlights the challenges of making the diagnosis of pericardial effusion in a 7-year-old boy.

## REFERENCES

[1] ABDEL-HAQ, N., MOUSSA, Z., FARHAT, M. H., et al. Infectious and noninfectious acute pericarditis in children: An 11-year experience. *Int J Pediatr* 2018; 2018: 5450697.

[2] BÉBÉAR, C.-M. Physiopathologie et diagnostic des infections à *Mycoplasma pneumoniae*. *Arch Pediatr* 2008;15:1253-6.

[3] Park, I. H., Du Young Choi, Y. K. O., Kim, J. D., & Yu, S. T. A case of acute myopericarditis associated with *Mycoplasma pneumoniae* infection in a child. *Korean Circ J* 2012; 42: 709.

[4] Principi N, Esposito S: Emerging role of *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in paediatric respiratory tract infections. *Lancet Infect Dis* 2001; 1: 334-44.

[5] Principi N, Esposito S: *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* cause lower respiratory tract disease in paediatric patients. *Curr Opin Infect Dis* 2002; 15: 295-300.

[6] Hawkins S, Rausch CM, McCanta AC. Constrictive pericarditis secondary to infection with *Mycoplasma pneumoniae*. *Curr Opin Pediatr* 2011;23:126-9.

[7] Mansel JK, Rosenow EC 3rd, Smith TF, Martin JW Jr. *Mycoplasma pneumoniae*. *Chest* 1989;95: 639-46.

[8] Paz A, Potasman I. *Mycoplasma*-associated carditis: case reports and review. *Cardiology* 2002;97:83-8.

[9] Defilippi A, Silvestri M, Tacchella A, et al. Epidemiology and clinical features of *Mycoplasma pneumoniae* infection in children. *Respir Med* 2008;102:1762-8.

[10] Waites KB, Talkington DF. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin Microbiol Rev* 2004;17:697-728.

[11] Esposito S, Bosis S, Begliatti E et al. Acute tonsillopharyngitis associated with atypical bacterial infection in children; natural history and impact of macrolide therapy. *Clin Infect Dis* 2006; 43: 206-9.

[12] Imazio M, Trinchero R. Myopericarditis: etiology, management, and prognosis. *Int J Cardiol* 2008;127:17-26.

[13] Johnson S. Possible autoantibody complications in *Mycoplasma pneumoniae* infection. *Clin Infect Dis* 2006; 43: 1246.

[14] Yamazaki T, Narita M, Sasaki N, Kenri T, Arakawa Y, Sasaki T. Comparison of PCR for sputum samples obtained by induced cough and serological tests for diagnosis of *Mycoplasma pneumoniae* infection in children. *Clin Vaccine Immunol* 2006; 13: 708-10.

[15] Guleira R, Nisar N, Chwla TC, Bismas NR. *Mycoplasma pneumoniae* and central nervous system complications: a review. *J Lab Clin Med* 2005; 146: 55-63.

[16] Suzuki S, Yamazaki T, Narita MN et al. Clinical evaluation of macrolide-resistant *Mycoplasma pneumoniae*. *Antimicrob Agents Chemother* 2006; 50: 709-12.

[17] Tsiodras S, Kelesidis I, Kelesidis T, Stamboulis E, Giamarellou H. Central nervous system manifestations of *Mycoplasma pneumoniae* infections. *J Infect* 2005;51:343-54.

[18] Leonardi S, Pavone P, Rotolo N, la Rosa M. Stroke in two children with *Mycoplasma pneumoniae* infection. A casual or causal relationship? *Pediatr Infect Dis J* 2005;24: 843-4.

[19] Lee KY, Lee HS, Hong J-H et al. Role of prednisolone treatment in severe *Mycoplasma pneumoniae* in children. *Pediatr Pulmonol* 2006; 41: 263-8.